Objective-Platelet adhesion to the subendothelial tissue via the collagen receptor ␣ 2 ␤ 1 is a crucial event in vascular biology. Although evidence has been provided that the number of platelets ␣ 2 ␤ 1 copies is genetically determined, the molecular change primary responsible has not been yet elucidated. The aim of our present study was to investigate the effect of combined polymorphisms within both regulatory (Ϫ52C/T and Ϫ92C/G) and coding regions (807C/T and 1648A/G) of the ␣ 2 subunit gene on human platelets ␣ 2 ␤ 1 receptor density and/or susceptibility to coronary artery disease (CAD). Methods and Results-Among 254 cardiac surgery patients, no evidence was found for an association between the ␣ 2 subunit gene polymorphisms and CAD. In contrast, in a subgroup of 113 patients, we observed a significant association between all polymorphisms except Ϫ52C/T and ␣ 2 ␤ 1 receptor level. Furthermore, when 3 groups of patients were defined according to the tertiles of platelets ␣ 2 ␤ 1 copies, the Ϫ92C/807T haplotype was more frequent in the group of patients with high ␣ 2 ␤ 1 receptor level. Conclusion-These results suggest that an individual effect of each polymorphism located either in the coding or promoter sequence of the ␣ 2 gene may act in combination to modulate variations in platelets ␣ 2 ␤ 1 receptor density. (Arterioscler Thromb Vasc Biol. 2005;25:1756-1760.) Key Words: Ϫ92C/G Ⅲ 807C/T polymorphism Ⅲ ␣ 2 ␤ 1 density Original
V essel wall injury triggers platelet activation and platelet plug formation, followed by the formation of fibrincontaining thrombi that occlude the site of injury. The interaction of platelet receptors with subendothelial components such as collagen is central to these events, which both limit blood loss at sites of tissue trauma but may also obstruct diseased vessels, leading to ischemia and infarction of vital organs. The direct platelet-collagen interaction is mediated by Ն2 receptors, the integrin ␣ 2 ␤ 1 and the nonintegrin receptor glycoprotein VI (GPVI), although there are likely to be others. 1 It is now considered that GPVI provides the primary collagen signal that activates and recruits the integrin receptor ␣ 2 ␤ 1 to further amplify collagen signals and fully activate platelets through a common intracellular signaling pathway. 2 Integrin ␣ 2 ␤ 1 is a heterodimer composed of 2 noncovalently associated subunits (␣ 2 and ␤ 1 ) that are encoded by separate genes. By virtue of its expression on platelets and vascular cells, [3] [4] [5] the integrin ␣ 2 ␤ 1 may play a significant role in vascular pathobiology. Among healthy individuals, platelet ␣ 2 ␤ 1 density is highly variable and correlates with the rate and extent of platelet adhesion to collagen type I or type III under static conditions. 4, 6 The differences in platelet ␣ 2 ␤ 1 density also correlate with the inheritance of certain allelic combinations, defined by linked polymorphisms within the coding sequence of the ␣ 2 gene. [7] [8] [9] [10] In addition, 2 single-base substitutions at positions Ϫ52 and Ϫ92 have been identified 11 within the "core" region defined by Zutter et al 12 in the proximal 5Ј-regulatory region of the gene. In vitro, the Ϫ52C/T and Ϫ92C/G dimorphisms have been shown to influence the rate of the ␣ 2 gene transcription in transfected human megakaryocytic cell lines. 11 It has also been suggested that 1 of the 2 promoter dimorphisms (Ϫ52C/T) could correlate with platelet ␣ 2 ␤ 1 density in healthy individuals. 13 A potentially important role for the ␣ 2 ␤ 1 integrin is suggested by recent epidemiologic data. 7, 14, 15 Several studies suggest a direct correlation between the genetically determined number of copies of ␣ 2 ␤ 1 at the platelet surface and the risk of thrombotic events. The T allele of 807C/T polymorphism, which is associated with high-level expression of ␣ 2 ␤ 1 on platelets, has been reported as an independent risk factor for myocardial infarction in selected groups of patients 16 -18 for the development of diabetic retinopathy in patients with type 2 diabetes mellitus 19 and for stroke in the young, 20 although other studies failed to find such a correlation. [21] [22] [23] [24] However, no data are yet available for the clinical impact of the dimorphisms present in the core region of the promoter that may modulate the expression of ␣ 2 ␤ 1 at the cell surfaces.
The aim of the present study was to examine the distribution of the Ϫ92C/G, Ϫ52C/T, 807C/T, and 1648A/G dimorphisms in a population of patients undergoing cardiac surgery and to analyze the influence of particular haplotypes on platelets ␣ 2 ␤ 1 receptor density. We hypothesized that the profile of an individual with combined polymorphisms in coding and regulatory regions of the ␣ 2 subunit gene may constitute a hereditary background for the susceptibility to the development of coronary artery disease (CAD).
Patients, Materials, and Methods

Patient Selection
The protocol was approved by the local ethics committee, and all patients gave their written informed consent to participate in the study. The total study population comprised 254 consecutive white patients (179 men and 75 women; 59Ϯ14 years of age) scheduled for either coronary artery bypass grafting or valve surgery. By means of coronary angiography, the study population was divided into patients with CAD (nϭ171) for subjects referred to the hospital for coronary artery bypass grafting in whom coronary artery stenosis was Ͼ70% (50% for left main artery) and non-CAD patients (nϭ83) for subjects referred to the hospital for valve surgery and without any angiographic signs of CAD (no atherosclerotic coronary plaque). We excluded patients with acute coronary syndrome who required emergency coronary artery bypass.
Blood Sampling
Blood sample was collected before coronary artery bypass or valve surgery. Blood was drawn in evacuated container tubes (Vacutainer; Becton Dickinson) containing EDTA for DNA analysis or 0.129 mol/L trisodium citrate for platelet ␣ 2 ␤ 1 density determination.
DNA Genotyping
We obtained genomic DNA from blood samples after extraction from blood leukocytes by a standard procedure with the QIAmp DNA blood Midi kit (Qiagen GmbH) according to manufacturer instructions.
We studied 2 nucleotide polymorphisms located at 807C/T bp and 1648A/G bp within the coding region of the ␣ 2 gene 25,26 and single-base substitutions at 2 positions, Ϫ92C/G and Ϫ52C/T, within the proximal 5Ј-regulatory region of the ␣ 2 gene. 13 Genotyping of these 4 polymorphisms was conducted using an adapted method of DNA amplification by polymerase chain reaction (PCR) procedure with specific primers. PCR products were digested by specific restriction enzymes and separated by appropriate electrophoresis.
Quantitation of Platelet ␣ 2 ␤ 1
We quantified the platelet ␣ 2 ␤ 1 level in a subgroup of 113 patients (CAD nϭ49; non-CAD nϭ64). Determination of platelet ␣ 2 ␤ 1 density was performed on citrated whole blood by flow cytometry using a kit "platelet Gp Screen test" (Biocytex). Briefly, whole blood was incubated with mouse monoclonal antibody against ␣ 2 ␤ 1 integrin (CD 69b) and followed by an incubation with a polyclonal antibody anti-mouse IgG coupled to fluorescein isothiocyanate. 27 Cytometric analysis was performed on a FACScalibur (Becton Dickinson). The number of platelet receptors was determined by converting the fluorescence intensity into corresponding number of sites per platelet on the basis of a calibrated bead standard curve using beads varying from Ϸ260 to 80 000 sites per platelet.
Statistical Analysis
Genotype distributions in different groups were compared by testing the hypothesis of homogeneity using 2 test and SAS software (SAS Institute; V8.0). Estimation of haplotype frequencies and linkage disequilibrium (D and DЈ) were computed using the Arlequin software V2.000. Data were expressed as meanϮSD and analyzed within genotype groups using ANOVA and Tukey-Kramer test for post hoc comparisons. For categorical variables and tertile comparisons, 2 test was performed. Differences were considered to be significant when PϽ0.05. Table 1 summarizes the genotype distribution of the 807C/T, 1648 A/G, Ϫ92 C/G, and Ϫ52 C/T polymorphisms of the ␣ 2 gene in the CAD and non-CAD groups. We reported similar genotype distribution in both groups. The genotype distribution is in agreement with the frequencies predicted by Hardy-Weinberg equilibrium (Pϭ0.76, Pϭ0.48, Pϭ0.54, and Pϭ0.38, respectively.)
Results
Distribution of the ␣ 2 Gene Polymorphisms
Measure of Linkage Disequilibrium Between ␣ 2 Gene Polymorphic Sites
In the total population of 254 patients, we investigated the linkage disequilibrium between the 4 polymorphic sites of ␣ 2 gene ( Table 2) . A significant linkage disequilibrium was observed between the 807C/T and 1648A/G polymorphisms and between the Ϫ52C/T and Ϫ92C/G polymorphisms within the proximal 5Ј regulatory region of the ␣ 2 gene: all patients carrying the Ϫ92C allele were found to carry the Ϫ52T allele.
In contrast, we observed a moderate linkage disequilibrium between the 807C/T and the promoter sequence Ϫ92C/G and Ϫ52C/T ( Table 2 ).
Relationship Between ␣ 2 Genotypes and Differences in Platelet ␣ 2 ␤ 1 Levels
A subgroup of 113 patients (CAD nϭ49; non-CAD nϭ64) was available for the measurement of platelet ␣ 2 ␤ 1 levels in whole blood by flow cytometry. No difference in ␣ 2 ␤ 1 density was observed between CAD and non-CAD patients (3960Ϯ1098 and 3881Ϯ1084 receptors per platelet, respectively). In consequence, the 2 groups were pooled to examine the relationship between genotypes and ␣ 2 ␤ 1 platelet density. In Figure 1 , the number of platelet ␣ 2 ␤ 1 copies per platelet is plotted according to the ␣ 2 genotypes within the coding sequence of each individual. As originally reported by Kunicki et al 28 and confirmed by others, 21, 29 in healthy subjects, we observed ( Figure 1A ) an association between ␣ 2 ␤ 1 densities and 807 polymorphism (ANOVA PϽ0.0001). Lowest ␣ 2 ␤ 1 densities (3200Ϯ906 receptors per platelet) were observed in 807CC patients; and conversely, highest receptor density in 807TT patients (4782Ϯ1216 receptors per platelet; PϽ0.05). In the same way, the platelet ␣ 2 ␤ 1 levels measured in 1648GG patients were lower than in heterozygous 1648AG patients (ANOVA Pϭ0.0082), reaching 3774Ϯ1090 and 4435Ϯ958 receptors per platelet, respectively (PϽ0.05). Unfortunately, no homozygous 1648AA patient was available for quantification of platelet ␣ 2 ␤ 1 copies.
Interestingly, we also found a significant correlation between the Ϫ92 C/G polymorphism and the platelet ␣ 2 ␤ 1 level (ANOVA Pϭ0.0056; Figure 2 ). The Ϫ92CC homozygous patients exhibited higher levels of ␣ 2 ␤ 1 receptors than the heterozygous Ϫ92CG patients (4066Ϯ1122 and 3384Ϯ744 receptors per platelet, respectively; PϽ0.05). The 4 homozygous patients for the Ϫ92 G allele had low density of ␣ 2 ␤ 1 (2810Ϯ646 receptors per platelet), but the difference with the Ϫ92CC homozygous did not reach significance. In contrast, the platelet ␣ 2 ␤ 1 receptor level was not found to be associated with the Ϫ52 C/T polymorphism (ANOVA Pϭ0.565) because density of ␣ 2 ␤ 1 varies between 3792Ϯ1115 receptors per platelet for Ϫ52CC and 3829Ϯ911 receptors per platelet for Ϫ52TT.
We looked for a possible influence of combined polymorphisms within regulatory and coding regions of the ␣ 2 subunit gene on human platelet ␣ 2 ␤ 1 receptor density. Because of the strong linkage disequilibrium between the 807C/T and 1648G/A polymorphisms on one hand, and the absence of association between the Ϫ52C/T polymorphism and the ␣ 2 ␤ 1 receptor density on the other hand, we determined the frequencies of haplotypes defined by the Ϫ92C/G and 807C/T polymorphisms in a panel of 113 patients in which the platelet ␣ 2 ␤ 1 receptor level has been quantified ( Table 3 ). Patients were studied according to tertiles of platelet ␣ 2 ␤ 1 receptor level: low (Ͻ3348 copies per platelet), medium (ranging from 3348 to 4191), and high (Ͼ4191) platelet ␣ 2 ␤ 1 receptor level. We observed that haplotype distribution was significantly different among the 3 groups of patients (ANOVA PϽ0.001). The most striking observation was that the Ϫ92C/807T haplotype is more frequent in the high-platelet ␣ 2 ␤ 1 receptor level group (0.60 versus 0.12 in the first tertile), whereas the Ϫ92G/807C haplotype is more frequent in the low-platelet ␣ 2 ␤ 1 receptor level group (0.16 versus 0.02 in the third tertile). Moreover, to determine whether this haplotype frequency was related to the linkage disequilibrium of polymorphisms or to the effect of each polymorphism, we compared the ␣ 2 ␤ 1 density according to the 807 genotype in the subgroup of 88 patients homozygous for Ϫ92C: significant differences in ␣ 2 ␤ 1 receptor level between 807TT, 807CT, and 807CC were observed, suggesting an individual effect of each polymorphism (ANOVA PϽ0.0001) and reaching 4872Ϯ1290, 4251Ϯ917, and 3316Ϯ912 receptors per platelet, respectively).
Discussion
Platelet adhesion to the subendothelial tissue via the collagen receptor ␣ 2 ␤ 1 is a crucial event in vascular biology and interindividual variations in ␣ 2 ␤ 1 expression levels could have a significant impact on vascular pathology and risk of arterial thrombosis. Although evidence has been provided that the number of platelets ␣ 2 ␤ 1 copies is genetically determined, 7-10 the molecular change primarily responsible has not been yet elucidated. The aim of our present study was to investigate the effect of combined polymorphisms within regulatory and coding regions of the ␣ 2 subunit gene on human platelet ␣ 2 ␤ 1 receptor density or susceptibility to CAD.
Among a total population of 254 patients, we report new data about the Ϫ92C/G, Ϫ52C/T, 807C/T, and 1648G/A polymorphic sites of the ␣ 2 gene. The linkage disequilibrium between the 807C/T and 1648A/G nucleotide polymorphisms on one hand, and between the Ϫ92C/G and Ϫ52C/T singlebase substitutions on the other hand, is confirmed, as reported previously by other groups. 26, 28 The platelet ␣ 2 ␤ 1 receptor quantification performed in freshly drawn whole blood also confirms that the level of collagen receptor ␣ 2 ␤ 1 can vary up to 4-fold among individuals. 6 As originally reported by Kunicki et al 28 in healthy subjects and confirmed by others, 10, 29 we observed an obvious association between the 807C allele and low ␣ 2 ␤ 1 level. However, homozygous patients for the 1648G allele exhibited the lowest ␣ 2 ␤ 1 density, in agreement with previous data of Corral et al. 10 No association was observed between the Ϫ52C/T dimorphism and platelet receptor density. Interestingly, we found that the platelet ␣ 2 ␤ 1 receptor level was significantly associated with the Ϫ92 C/G promoter nucleotide dimorphism. This finding is supported by the previous work of Jacquelin et al, 13 demonstrating that in vitro, in transfected human megakaryocytic cell lines, the Ϫ92G promoter sequence has a negative regulatory effect on the ␣ 2 gene transcription. Altogether, these findings emphasize the potential importance of the Ϫ92C promoter substitution on human platelet ␣ 2 ␤ 1 receptor expression.
When 3 groups of patients were defined according to the tertiles of the number of platelets ␣ 2 ␤ 1 copies, it appeared that haplotype distribution was different: the Ϫ92G/807C haplotype was more frequent in the group of patients with low ␣ 2 ␤ 1 receptor levels, whereas the Ϫ92C/807T haplotype was in a large majority found in the group of patients with high ␣ 2 ␤ 1 receptor levels. Moreover, in the subgroup of patients, Ϫ92CC significant differences of ␣ 2 ␤ 1 density were observed according to 807C/T polymorphism. Because of moderate linkage disequilibrium between the Ϫ92C/G and 807C/T polymorphisms, the present results confirm evidence for more than a single genetic factor involved in the number of ␣ 2 ␤ 1 molecules per platelet. Our findings indicate that an individual effect of each polymorphism in either the coding or promoter sequence may act in combination to modulate variation in receptor density. Although the Ϫ92C/G promoter substitution may have a direct impact on expression levels of ␣ 2 gene, the silent 807C/T polymorphism within the coding sequence that does not modify the deduced amino acid sequence of the translated protein may be linked to other polymorphisms within the ␣ 2 gene, which remain to be determined.
Looking for a clinical relevance of the ␣ 2 alleles, we investigated the relationship between the platelet ␣ 2 ␤ 1 receptor density and nucleotide polymorphisms of the ␣ 2 subunit gene and CAD. No significant difference was observed in the surface expression of platelet ␣ 2 ␤ 1 in CAD versus non-CAD patients. It is likely that the ␣ 2 ␤ 1 receptor number alone is not sufficient to compromise platelet function and an individual's susceptibility to arterial diseases, which are probably under the dependence of an other major collagen receptor, GPVI, 30 or of other platelet receptors such as GPIb or ␣ 2b ␤ 3 . Abnormalities of the vessel wall (as atherosclerosis) could also modulate platelet adhesion. Genotype distributions and allele frequencies were not significantly different in CAD versus non-CAD patients. With regard to nucleotide polymorphisms located within the coding region of the gene, several previous reports have extensively studied 807C/T and 1648A/G dimorphisms. In agreement with us, some authors failed to show an association between 807C/T polymorphism and CAD, 21, 22, 24, 31 whereas conflicting studies showed a significant correlation between 807T allele and myocardial infarction. 16, 17 Furthermore, Kroll et al found in a large population a significant association between the 1648A/G polymorphism and CAD. 32 Possible explanations for these apparent discrepancies may be the differences of population size and the fact that numerous other factors are involved in the progression of atherosclerosis. Furthermore, our negative results may be attributable to the choice of an anatomic (angiographic) criteria rather than a more clinically relevant one such as evolutivity of coronary disease (occurrence of acute coronary syndrome).
In summary, we showed evidence for a possible influence of the inheritance of particular haplotypes of ␣ 2 gene on differences in human platelet ␣ 2 ␤ 1 receptor density. Our results suggest an important combined effect of the Ϫ92C and 807T nucleotide sequences in increasing the expression of human platelet ␣ 2 ␤ 1 receptors. These results must be confirmed in a larger study to precisely determine the involvement of the ␣ 2 gene allelic combinations in coronary disease through the platelet ␣ 2 ␤ 1 receptor expression. Further studies are also required in a larger population to test whether or not the Ϫ92C/G and 807C/T polymorphisms have a functional effect on gene expression, and, if not, to identify the causal single-nucleotide polymorphisms in linkage disequilibrium with Ϫ92C/G and 807C/T polymorphisms. A more generalized haplotype strategy on the basis of polymorphisms described in single-nucleotide polymorphism databases would probably be most pertinent.
